With more than 2 million patients on some form of dialysis around the world, and dialysis treatment rates rising more than 5% annually, it isn’t hard to discern the reasoning behind Baxter International’s (NYSE: BAX) $4 billion bid for Gambro AB, a privately held dialysis product company based in Lund, Sweden.  Baxter’s broad dialysis product portfolio fits well with Gambro’s extensive European presence, while Baxter’s reach in Latin America and Asia Pacific will benefit Gambro’s product line. JP Morgan acted as financial advisor and Kirkland & Ellis LLP served as legal advisor to Baxter.
Following its previously announced acquisition of Sync-RX Ltd. in November, Volcano Corporation (NASDAQ: VOLC) wasted little time in announcing a deal for Crux Biomedical, Inc. on December 3, 2012, for $39.1 million. Volcano develops and makes a suite of intravascular ultrasound and measurement products used to diagnose and treat vascular and structural heart disease. Crux’s main product, an inferior vena cava filter (IVCF) known as the Crux VCF System, treats pulmonary embolisms. The IVC filter market in the U.S. is estimated at approximately $300 million annually.
Cataract surgery has come to seem routine, given that cataracts are the leading cause of blindness worldwide…….Want to read more? Click here for a free trial to The Health Care M&A Information Source and download the current issue today